Nurses Compass
Drug Guide
Tecovirimat
Classification
Therapeutic: Antiviral agent
Pharmacological: Viral replication inhibitor
FDA Approved Indications
- Treatment of smallpox virus (variola virus) infections
Mechanism of Action
Tecovirimat inhibits the activity of the viral envelope protein VP37, preventing the formation of egress-competent enveloped virions and thereby blocking virus dissemination within the host.
Dosage and Administration
Adult: 600 mg orally twice daily for 14 days
Pediatric: Not established, use optimization pending further data
Geriatric: No specific adjustments needed but monitor for tolerability
Renal Impairment: No dose adjustment recommended
Hepatic Impairment: No dose adjustment recommended
Pharmacokinetics
Absorption: Well absorbed orally
Distribution: Wide distribution; specific data limited
Metabolism: Primarily through hydrolysis and possibly CYP-mediated pathways
Excretion: Primarily via feces, minimal urinary excretion
Half Life: approximately 20 hours
Contraindications
- Known hypersensitivity to tecovirimat
Precautions
- Use with caution in immunocompromised individuals; monitor for adverse effects
Adverse Reactions - Common
- Headache (Common)
- Nausea (Common)
- Vomiting (Common)
Adverse Reactions - Serious
- Severe allergic reactions (Rare)
- Hepatic toxicity (Rare)
Drug-Drug Interactions
- None well-established, but avoid concomitant use with drugs affecting CYP pathways pending further data
Drug-Food Interactions
- None specifically indicated
Drug-Herb Interactions
- None established
Nursing Implications
Assessment: Assess patient for history of hypersensitivity and baseline hepatic function
Diagnoses:
- Risk for infection
- Potential adverse drug reactions
Implementation: Administer as prescribed; monitor for adverse effects and efficacy
Evaluation: Assess resolution or improvement of infection signs and tolerability
Patient/Family Teaching
- Take medication exactly as prescribed for the full course
- Report any signs of allergic reactions or unusual symptoms immediately
- Maintain good hygiene to prevent secondary infection
Special Considerations
Black Box Warnings:
- None currently issued
Genetic Factors: Not applicable
Lab Test Interference: No known interference with routine lab tests
Overdose Management
Signs/Symptoms: Potential increased risk of adverse effects, including hepatic toxicity
Treatment: Supportive care; no specific antidote
Storage and Handling
Storage: Store at room temperature, 20°C to 25°C (68°F to 77°F)
Stability: Stable under recommended storage conditions for duration specified in packaging